Table 2.
LogCCID50 loss for MR HD-MAPs and MR-Vac stored at 2–8 °C (pre-clinical studies).
| Group | Time and Condition |
LogCCID50 Loss (95% CI) |
|||
|---|---|---|---|---|---|
| Measles | Rubella | ||||
| MR HD-MAP |
MR-Vac | MR HD-MAP |
MR-Vac | ||
| Accelerated 1 | 3 days, 40 °C | 0.39 (0.29–0.49) |
0.37 (0.17–0.55) |
0.16 (−0.06–0.38) |
0.00 (−0.19–0.19) |
| 7 days, 37 °C | 0.43 (0.33–0.53) |
0.50 (0.31–0.69) |
0.07 (−0.01–0.15) |
0.33 (0.00–0.66) |
|
| 14 days, 37 °C | 0.35 (0.26–0.44) |
0.55 (0.55–0.55) |
0.17 (−0.02–0.36) |
0.05 (−0.35–0.45) |
|
| Long-term 2 | 6 months, 25 °C | 0.67 (0.55–0.79) |
0.75 (0.28–1.22) |
0.24 (0.07–0.41) |
0.23 (0.16–0.31) |
| 30 months, 2–8 °C | 0.38 (0.21–0.55) |
0.47 (0.35–0.59) |
0.18 (0.13–0.23) |
−0.03 (−0.25–0.19) |
|
| Long-term (clinical) 2 | 24 months, 2–8 °C | 0.06 (−0.15–0.27) |
Not carried out | 0.29 (0.11–0.47) |
Not carried out |
Notes: 1—compared to 2–8 °C samples assayed in parallel; 2—compared to T0. All accelerated conditions were performed at 60 ± 5% RH. For reference, long-term data from the clinical batch are shown in Figure 3.